Business Context and Reporting Period
This Form 8-K Current Report was filed by Eyenovia, Inc. (not Hyperion DeFi, Inc.) on March 7, 2022, covering events occurring on March 3 and March 4, 2022. The Company is a Delaware corporation listed on the Nasdaq Capital Market under the symbol "EYEN" and is classified as an emerging growth company.
Key Financial Metrics and Transaction Details
The filing details a private placement offering with the following financial terms:
- Aggregate Gross Proceeds: Approximately $15 million (excluding proceeds from the exercise of Pre-Funded Warrants and Warrants).
- Securities Issued:
- 3,000,000 shares of Common Stock at $3.08 per share.
- 4,870,130 Warrants to purchase Common Stock at an exercise price of $3.54 per share.
- 1,870,130 Pre-Funded Warrants at $3.07 per warrant (exercisable immediately).
- Use of Proceeds: Advancement of the MydCombi program (including manufacturing ramp-up), the MicroLine clinical program, and working capital/general corporate purposes.
- Intermediaries: No underwriter or placement agent participated in the offering.
Note: This filing does not provide standard financial metrics such as revenue, net profit, operating cash flow, margins, or total debt levels.
Material Changes
The primary material change is the execution of a securities purchase agreement with an institutional and accredited investor. This transaction increases the Company's equity capital base and introduces new warrant obligations. The filing does not provide comparative financial data against prior periods to quantify changes in revenue or profitability.
Outlook, Risks, and Management Commentary
Management Commentary: The Company intends to utilize the net proceeds to accelerate its core clinical programs, specifically MydCombi and MicroLine, and to enhance manufacturing capabilities.
Risks and Contingencies: The Purchase Agreement contains customary representations, warranties, and indemnification obligations. The terms of the warrants and pre-funded warrants are subject to the specific conditions outlined in the exhibits (Exhibits 4.1, 4.2, and 10.1). The Warrants are exercisable beginning six months from issuance and terminate five years from the initial exercisability date.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received, as the $15 million figure is an expectation.
- Review the full text of the Purchase Agreement (Exhibit 10.1) for specific covenants, redemption rights, or registration rights that may impact future capital structure.
- Confirm the dilution impact of the 3,000,000 shares plus the potential exercise of 6,740,260 warrants/pre-funded warrants on existing shareholders.
- Check subsequent filings for updates on the status of the MydCombi and MicroLine clinical programs funded by this capital.